U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H28N.Br
Molecular Weight 362.347
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EMEPRONIUM BROMIDE

SMILES

[Br-].CC[N+](C)(C)C(C)CC(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=UVKFSMBPRQBNCH-UHFFFAOYSA-M
InChI=1S/C20H28N.BrH/c1-5-21(3,4)17(2)16-20(18-12-8-6-9-13-18)19-14-10-7-11-15-19;/h6-15,17,20H,5,16H2,1-4H3;1H/q+1;/p-1

HIDE SMILES / InChI
Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C20H28N
Molecular Weight 282.443
Charge 1
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Emepronium bromide (Cetiprina) is a quarternary ammonium compound with anticholinergic effects. It is mainly used in the treatment of urinary frequency, urge and urge incontinence and is usually administered orally and occasionally intramuscularly. Emepronium bromide was introduced into Britain, after having been used in Sweden for a number of years. The drug was advocated especially for elderly patients suffering from nocturia and urgency with incontinence, when these were due to causes other than obstruction. It was also advocated for enuresis and hypertonic bladder states following surgery or radiotherapy.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Modulator
828
PubMed

PubMed

TitleDatePubMed
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.
2002
Drug-induced esophagitis.
2009
Oxybutynin extended release for the management of overactive bladder: a clinical review.
2009 Sep 21
Medical management of overactive bladder.
2010 Apr
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Severe odynophagia in a patient developing after azithromycin intake: a case report.
2010 Feb 3
[A drug seeks its disease].
2010 Jun 2-8
Patents

Patents

WO2012055018
2

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Emepronium bromide is commercially available as a parenteral solution, (25 mg/ml) for intramuscular use.
Intravenous doses of 1, 5, 10 and 15 mg of emepronium bromide were given to three healthy volunteers.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:03:47 UTC 2023
Edited
by admin
on Fri Dec 15 18:03:47 UTC 2023
Record UNII
WZM699L2TL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EMEPRONIUM BROMIDE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
BENZENEPROPANAMINIUM, N-ETHYL-N,N,.ALPHA.-TRIMETHYL-.GAMMA.-PHENYL-, BROMIDE (1:1)
Systematic Name English
Emepronium bromide [WHO-DD]
Common Name English
CETIPRIN
Brand Name English
EMEPRONIUM BROMIDE [MART.]
Common Name English
RESTENACHT
Brand Name English
AMMONIUM, ETHYLDIMETHYL(1-METHYL-3,3-DIPHENYLPROPYL)-, BROMIDE
Systematic Name English
URO-RIPIRIN
Brand Name English
ETHYLDIMETHYL(1-METHYL-3,3-DIPHENYLPROPYL)AMMONIUM BROMIDE
Systematic Name English
HEXANIUM
Systematic Name English
EMEPRONIUM BROMIDE [MI]
Common Name English
BENZENEPROPANAMINIUM, N-ETHYL-N,N,.ALPHA.-TRIMETHYL-.GAMMA.-PHENYL-, BROMIDE
Systematic Name English
emepronium bromide [INN]
Common Name English
RIPIRIN
Brand Name English
Code System Code Type Description
EPA CompTox
DTXSID50875265
Created by admin on Fri Dec 15 18:03:47 UTC 2023 , Edited by admin on Fri Dec 15 18:03:47 UTC 2023
PRIMARY
WIKIPEDIA
EMEPRONIUM BROMIDE
Created by admin on Fri Dec 15 18:03:47 UTC 2023 , Edited by admin on Fri Dec 15 18:03:47 UTC 2023
PRIMARY
PUBCHEM
71820
Created by admin on Fri Dec 15 18:03:47 UTC 2023 , Edited by admin on Fri Dec 15 18:03:47 UTC 2023
PRIMARY
ChEMBL
CHEMBL2110805
Created by admin on Fri Dec 15 18:03:47 UTC 2023 , Edited by admin on Fri Dec 15 18:03:47 UTC 2023
PRIMARY
MERCK INDEX
m4885
Created by admin on Fri Dec 15 18:03:47 UTC 2023 , Edited by admin on Fri Dec 15 18:03:47 UTC 2023
PRIMARY Merck Index
SMS_ID
100000080217
Created by admin on Fri Dec 15 18:03:47 UTC 2023 , Edited by admin on Fri Dec 15 18:03:47 UTC 2023
PRIMARY
EVMPD
SUB06504MIG
Created by admin on Fri Dec 15 18:03:47 UTC 2023 , Edited by admin on Fri Dec 15 18:03:47 UTC 2023
PRIMARY
NCI_THESAURUS
C169941
Created by admin on Fri Dec 15 18:03:47 UTC 2023 , Edited by admin on Fri Dec 15 18:03:47 UTC 2023
PRIMARY
RXCUI
71481
Created by admin on Fri Dec 15 18:03:47 UTC 2023 , Edited by admin on Fri Dec 15 18:03:47 UTC 2023
PRIMARY RxNorm
FDA UNII
WZM699L2TL
Created by admin on Fri Dec 15 18:03:47 UTC 2023 , Edited by admin on Fri Dec 15 18:03:47 UTC 2023
PRIMARY
ECHA (EC/EINECS)
222-786-6
Created by admin on Fri Dec 15 18:03:47 UTC 2023 , Edited by admin on Fri Dec 15 18:03:47 UTC 2023
PRIMARY
INN
2414
Created by admin on Fri Dec 15 18:03:47 UTC 2023 , Edited by admin on Fri Dec 15 18:03:47 UTC 2023
PRIMARY
CAS
3614-30-0
Created by admin on Fri Dec 15 18:03:47 UTC 2023 , Edited by admin on Fri Dec 15 18:03:47 UTC 2023
PRIMARY
Related Record Type Details
Structure of EMEPRONIUM BROMIDE, (R)-
ENANTIOMER -> RACEMATE
Structure of EMEPRONIUM
PARENT -> SALT/SOLVATE
Structure of EMEPRONIUM BROMIDE, (S)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of EMEPRONIUM
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966